Skip to content

Inspection Record

Linhai Tianyu Pharmaceutical Co., Ltd. — FDA 483 Findings

US FDAInspected 2023-09-15Published 2026-11-13 3 findingsEquipment and facilityLaboratory and QC controlsComputer system validation

Inspectors Arsen Karapetyan · Anders W. EvensonThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Facilities and equipment used in the manufacturing of drug substances are not adequately maintained.

2Laboratory and QC controls

Laboratory records are not completed contemporaneously and do not include complete data derived from all tests to assure compliance with established specifications and standards.

3Computer system validation

Appropriate controls are not exercised over computers or related systems to assure that changes in quality control records are instituted only by authorized personnel.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Linhai Tianyu Pharmaceutical Co., Ltd. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.